Related Experiment Video

Updated: Nov 2, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K

Role of noncoding RNA in drug resistance of prostate cancer

Lifeng Ding1, Ruyue Wang1, Danyang Shen1

  • 1Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Cell Death & Disease
|June 9, 2021
PubMed

Insights

Noncoding RNAs, including microRNAs, long noncoding RNAs, and circular RNAs, play a key role in overcoming prostate cancer drug resistance. Understanding these molecules offers new therapeutic strategies for treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer is a global health concern, with androgen-deprivation therapy and chemotherapy as primary treatments.
  • Drug resistance remains a significant challenge in managing advanced prostate cancer.
  • Noncoding RNAs (ncRNAs) are increasingly recognized for their regulatory roles in cellular functions and disease development.

Purpose of the Study:

  • To review the critical roles of microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) in the development of drug resistance in prostate cancer.
  • To explore the potential of these ncRNAs as therapeutic targets for overcoming treatment resistance.

Main Methods:

  • Literature review of recent studies on noncoding RNAs and prostate cancer drug resistance.
  • Analysis of the mechanisms by which miRNAs, lncRNAs, and circRNAs influence therapeutic outcomes.
  • Synthesis of information regarding the clinical relevance and therapeutic potential of ncRNAs.

Main Results:

  • Evidence highlights the involvement of miRNAs, lncRNAs, and circRNAs in mediating resistance to androgen-deprivation therapy and chemotherapy.
  • Specific ncRNAs have been identified that promote or suppress drug resistance through various molecular pathways.
  • Dysregulation of these ncRNAs is a common feature in treatment-resistant prostate cancer.

Conclusions:

  • Noncoding RNAs are pivotal regulators in the emergence of prostate cancer drug resistance.
  • Targeting specific miRNAs, lncRNAs, and circRNAs presents a promising avenue for novel therapeutic strategies.
  • Further research into ncRNA functions could lead to improved treatment outcomes for patients with resistant prostate cancer.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.0K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.4K

Related Concept Videos

Types of RNA01:20

Types of RNA

Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
7.4K
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
70.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K